Search Results - "Horton, Clive"

Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial by Powles, Ray, Mehta, Jayesh, Kulkarni, Samar, Treleaven, Jennifer, Millar, Barbara, Marsden, Jill, Shepherd, Val, Rowland, April, Sirohi, Bhawna, Tait, Diana, Horton, Clive, Long, Simon, Singhal, Seema

“…Atologous transplantation with peripheral blood stem cells (PBSC) results in faster haematopoietic-cell repopulation than with bone marrow. We prospectively…”
Get full text

The role of second autografts in the management of myeloma at first relapse by Alvares, CL, Davies, FE, Horton, C, Patel, G, Powles, R, Morgan, GJ

“…We report an analysis of the value of a second high-dose melphalan autograft, performed at relapse, on a series of newly diagnosed myeloma patients entered…”
Get full text

Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants by KULKARNI, S, POWLES, R, MEHTA, J, TRELEAVEN, J, RILEY, U, SINGHAL, S, HORTON, C, SIROHI, B, BHAGWATI, N, MELLER, S, SASO, R

“…Incidences of and risk factors for Streptococcus pneumoniae sepsis (SPS) after hematopoietic stem cell transplantation were analyzed in 1329 patients treated…”
Get full text

Identification of Patients Who May Benefit From Prophylactic Immunotherapy After Bone Marrow Transplantation for Acute Myeloid Leukemia on the Basis of Lymphocyte Recovery Early After Transplantation by Powles, Ray, Singhal, Seema, Treleaven, Jennifer, Kulkarni, Samar, Horton, Clive, Mehta, Jayesh

“…Two hundred and one patients (median age, 29 years) with acute myeloid leukemia (AML) underwent bone marrow transplantation (BMT) from HLA-identical sibling…”
Get full text

Tailored service: Community learning disability nursing is constantly evolving to meet the health needs of a varied client group by Horton, Clive

Get full text

The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis by Wu, Ping, Davies, Faith E., Horton, Clive, Jenner, Matthew W., Krishnan, Biju, Alvares, Caroline L., Saso, Radovan, Mccormack, Rita, Dines, Sharon, Treleaven, Jennifer G., Potter, Michael N., Ethell, Mark E., Morgan, Gareth J

“…A retrospective case-matched study was conducted to compare the oral regimen CTD (cyclophosphamide - thalidomide - dexamethasone) and infusional CVAMP…”
Get full text

Informed consent is a health issue by Horton, Clive

Get full text

Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments by Alvares, Caroline L., Davies, Faith E., Horton, Clive, Patel, Gita, Powles, Ray, Sirohi, Bhawna, Zuha, Roslin, Gatt, Alex, Saso, Radovan, Treleaven, Jennifer G., Dearden, Claire E., Potter, Michael N., Ethell, Mark E., Morgan, Gareth J.

“…Summary Induction chemotherapy followed by high‐dose melphalan (HDM) is the standard treatment for fitter patients with myeloma. The place of bortezomib and…”
Get full text

Incidence of Second Malignant Neoplasms (SMN) after Haematopoetic Stem Cell Transplant by Kulkarni, Samar, Potter, Michael, Ethell, Mark, Saso, Radovan, Treleaven, Jennifer, Brennan, Joy, Kaczmarek, Pawel, Hiwarkar, Prashant, Kanagasabapathy, Pamala, Alvares, Caroline, Horton, Clive, Powles, Raymond, Saran, Frank, Morgan, Gareth

“…From August 1973 to December 2003, 1651 patients (median age: 28yr., range: 1–74 yr.; M: 982, F: 669) received stem cell transplants for haematological…”
Get full text

Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation by Alvares, Caroline, Kulkarni, Samar, Kaczmarek, Pawel, Saso, Radovan, Woods, Helena, Brennan, Joy, Horton, Clive, Treleaven, Jennifer, Ethell, Mark, Dearden, Claire, Morgan, Gareth, Potter, Michael

“…In vivo T-cell depletion using Alemtuzumab containing conditioning regimens are commonly employed in high risk patients undergoing non-myeloablative allogeneic…”
Get full text

Recipient CMV Seropositivity Predicts Relapse Post Allogeneic Transplantation in Children by Zuha, Roslin, Gatt, Alex, Alvares, Caroline, Horton, Clive, Patel, Gita, Ethell, Mark, Potter, Michael

“…The importance of recipient CMV status is established as a major determinant of post transplantation infection risk, however studies to date have so far not…”
Get full text

Pregnancy Outcome Following Haematopoietic Stem Cell Transplantation by Kulkarni, Samar, Ethell, Mark, Treleaven, Jennifer, Saso, Radovan, Brennan, Joy, Kaczmarek, Pawel, Alvares, Caroline, Horton, Clive, Saran, Frank, Kanagasabapathy, Pamala, Hiwarkar, Prashant, Appiah-Cubi, Stella, Dungarwala, Moez, Powles, Raymond, Morgan, Gareth, Potter, Michael

“…Between March 1973 and August 2003, 747 patients (M: 430, F:317; median age: 29yr, range:1–65) who survived for at least 1 yr. post stem cell transplant and…”
Get full text

Responses to Induction Chemotherapy and High Dose Melphalan Can Be Incorporated within a Risk Stratification Model and Help to Identify Myeloma Patients Who May Benefit from Novel Therapies by Alvares, Caroline L., Davies, Faith E., Horton, Clive, Patel, Gita, Zuha, Roslin, Gatt, Alex, Saso, Radovan, Treleaven, Jennifer, Ethell, Mark, Potter, Mike, Dearden, Claire, Morgan, Gareth J.

“…We propose a multi-parametric risk stratification model for the identification of patients with myeloma who may benefit from novel therapies. This model is…”
Get full text

Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy by Sirohi, Bhawna, Powles, Ray, Cavanagh, Jamie, Oakervee, Heather, Dyer, P, Rintala, T, Kulkarni, Samar, Rudin, Claudius, Horton, Clive, Treleaven, Jennifer, Morgan, Gareth

“…The aim of the study was to evaluate whether adequate stem cells (CD34+) could be harvested at presentation in myeloma patients such that high dose melphalan…”
Get more information

Tailored service by Horton, C

Get full text

Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system by Sirohi, Bhawna, Powles, Ray, Mehta, Jayesh, Raje, Noopur, Kulkarni, Samar, Ramiah, Veshana, Saso, Radovan, Horton, Clive, Bhagwati, Niyati, Singhal, Seema, Treleaven, Jennifer

“…Because the presence of IgG paraprotein in the blood is clear cut, it makes IgG myeloma a more circumscribed disease than myeloma as a whole in which to study…”
Get full text

Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft by Sirohi, Bhawna, Powles, Ray, Rudin, Claudius, Singhal, Seema, Kulkarni, Samar, Saso, Radovan, Horton, Clive, Mehta, Jayesh, Treleaven, Jennifer

“…If standard infusional therapy (IC) has been used to treat myeloma at presentation, it is a matter of debate whether patients should receive the original…”
Get more information

Number of Nucleated Cells Infused During Allogeneic and Autologous Bone Marrow Transplantation: An Important Modifiable Factor Influencing Outcome by Mehta, Jayesh, Powles, Ray, Treleaven, Jennie, Kulkarni, Samar, Horton, Clive, Singhal, Seema

Get full text

Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants by Kulkarni, Samar, Powles, Ray, Treleaven, Jennie, Riley, Unell, Singhal, Seema, Horton, Clive, Sirohi, Bhawna, Bhagwati, Niyati, Meller, Simon, Saso, Radovan, Mehta, Jayesh

“…Incidences of and risk factors for Streptococcus pneumoniaesepsis (SPS) after hematopoietic stem cell transplantation were analyzed in 1329 patients treated at…”
Get full text

Growth of human T-cell lineage acute leukemia in severe combined immunodeficiency (SCID) mice and non-obese diabetic SCID mice by STEELE, J. P. C, CLUTTERBUCK, R. D, POWLES, R. L, MITCHELL, P. L. R, HORTON, C, MORILLA, R, CATOVSKY, D, MILLAR, J. L

“…Primary leukemic cells from patients with acute lymphoblastic leukemia (ALL) can be injected intravenously into mice with severe combined immunodeficiency…”
Get full text